Consistent with the previous studies, CXCL10-positive tumors had higher antigen processing, antitumor immune response, and TIL accumulation (Au et al., 2017; Theodoraki et al., 2018; Unger et al., 2018), thereby suggesting that CXCL10 expression is a predictive biomarker to evaluate immune cell infiltration in ovarian cancer TME. This evidence concerns the gene CXCL10 and ovarian cancer.